Skip to main content
. Author manuscript; available in PMC: 2016 Oct 15.
Published in final edited form as: Clin Cancer Res. 2015 Jun 18;21(20):4642–4651. doi: 10.1158/1078-0432.CCR-15-0781

Figure 2.

Figure 2

Effect of ibrutinib on cellular adhesion to fibronectin. A, Representative microphotographs showing the number of CLL PBMCs adhered to a fibronectin coated plate after 1 hour incubation; top panel, sample collected pre-treatment (Pre), bottom panel, sample collected on study day 28 from the same patient. B, The number of adherent cells per visual field is shown for PBMCs obtained pre-treatment and after 28 days on ibrutinib (n=13). Each symbol represents a different patient, lines represent the median. C, The number of adherent cells per visual field is shown for PBMCs obtained pre-treatment and after 24 hours on ibrutinib (n=10). Each symbol represents a different patient, lines represent the median. D, The median cell count per visual field is shown for PBMCs obtained pre-treatment (Pre), on day 2, and day 28. Lines connect data points from sequential samples of the same patient (n=8). All Statistics were determined by a Wilcoxon matched pairs test.